Company: HRTX
Filing Date: 2025-09-09
Form Type: PRE 14A
Source: 0000950170-25-113827
Chunk: 15

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-09-09
Form: PRE 14A
Chunk 15
---
 stockholders in the voting power, any liquidation value, our book and market value, and in any future earnings. Further, the issuance or resale of the Preferred Stock Shares could cause the market price of our Common Stock to decline. The increased number of shares issued could discourage the possibility of, or render more difficult, certain mergers, tender offers, proxy contests or other change of control or ownership transactions.

If our stockholders do not approve this Proposal, then the Series A Convertible Preferred Stock will not be convertible into Common Stock, and such Series A Preferred Stock will remain outstanding.

Additional Information

This summary is intended to provide you with basic information concerning the Purchase Agreement, the Series A Convertible Preferred Stock and the possible Preferred Stock Issuances. The terms of the Purchase Agreement, Series A Preferred Stock and the possible Preferred Stock Issuances are complex and only briefly summarized above. For further information, please refer to the descriptions contained in the Company’s Current Reports on Form 8-K filed with the SEC on August 8, 2025 and August 12, 2025 and the documents filed as exhibits to such reports. The discussion herein is qualified in its entirety by reference to such transaction documents filed with the SEC.

Vote Required and Board Recommendation

The approval of Proposal 2 requires a quorum of the Company’s stockholders. A quorum will be present at the meeting if the holders of a majority of the shares of stock, issued and outstanding and entitled to vote, are present in person or represented by proxy. To approve Proposal 2, holders of a majority of the votes cast on the matter must vote FOR the proposal. Only FOR and AGAINST votes will affect the outcome. Abstentions and broker non-votes will have no effect on the voting of Proposal 2.

Proposal 2 is not a routine matter. Therefore, if your shares are held by your bank, broker or other nominee in street name and you do not vote your shares, your bank, broker or other nominee may not vote your shares on Proposal 2.

The Board of Directors recommends a vote “FOR” the Preferred Stock Issuance, including an amount above 19.99% of the number of shares of the Company’s Common Stock issued and outstanding prior to such issuance.

<div align='center'>13

OTHER MATTERS</div>

As of the date of this Proxy Statement, the Board knows of no matter that will be presented for action by our stockholders at the Special Meeting other than those discussed in this Proxy Statement.